Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-03-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司非布司他原料药通过CDE审批的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical raw material by the National Medical Products Administration's Center for Drug Evaluation (CDE). It provides details about the approval status and implications for the company's product line. The document is short (699 characters) and serves as a regulatory update rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or voting results. It is an official regulatory announcement about product approval, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-03-21 Chinese
关于第一期员工持股计划存续期即将届满的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the expiration of the first employee stock ownership plan. It details the plan's background, shareholding situation, and arrangements before the plan's expiration. The document is relatively short (1969 characters) and serves as a notification or reminder about the plan's status rather than a detailed financial report or analysis. It does not contain financial statements, audit information, or management discussion. It is an announcement related to employee stock ownership plans, which is a capital/financing related update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-02-07 Chinese
关于注射用头孢美唑钠通过仿制药质量和疗效一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (786 characters) from a company about its product (injection drug) passing a regulatory consistency evaluation by the National Medical Products Administration (国家药品监督管理局). It contains no financial data, no report or financial statements, and no mention of shareholder meetings or voting results. It is a regulatory announcement about product approval and quality evaluation. The document is not a report itself but an announcement of regulatory approval. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-25 Chinese
关于深圳证券交易所《关注函》回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company responding to a regulatory inquiry (关注函) from the Shenzhen Stock Exchange regarding a specific transaction involving the repurchase of a 51% equity stake in a subsidiary. It discusses the status of payments, legal actions, risks, and company measures. The content is focused on regulatory compliance, legal and financial risk disclosures, and ongoing litigation preparations rather than presenting a full financial report or earnings data. The document is over 5,000 characters and contains substantive information but is primarily a regulatory response to a stock exchange inquiry. It does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other financial reports. It is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement responding to an exchange's concern letter and discloses material information about the company's legal and financial situation related to a transaction.
2022-01-21 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a short announcement (785 characters) regarding the release of pledged shares by a controlling shareholder. It details the shareholder's name, number of shares released from pledge, and related dates. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. This fits the category of a Major Shareholding Notification, as it informs about changes in significant share ownership or share pledging status by a major shareholder.
2022-01-14 Chinese
关于子公司收到多索茶碱注射液药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (729 characters) regarding a subsidiary receiving a drug registration certificate from the National Medical Products Administration. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official announcement about a regulatory approval event. The document is not a report itself but a regulatory announcement about a certificate issuance. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-01-13 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.